EquityIndex FundsVery High Risk
Direct
NAV (03-Dec-24)
Returns (Since Inception)
Fund Size
₹18 Cr
Expense Ratio
0.22%
ISIN
INF194KB1IS2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
06 Sep 2024
Equity | ₹17.63 Cr | 100.06% |
Others | ₹-0.01 Cr | -0.06% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹2.72 Cr | 15.45% |
Cipla Ltd | Equity | ₹1.18 Cr | 6.70% |
Dr Reddy's Laboratories Ltd | Equity | ₹1.06 Cr | 6.01% |
Divi's Laboratories Ltd | Equity | ₹1.02 Cr | 5.81% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.02 Cr | 5.81% |
Apollo Hospitals Enterprise Ltd | Equity | ₹0.95 Cr | 5.41% |
Lupin Ltd | Equity | ₹0.72 Cr | 4.09% |
Aurobindo Pharma Ltd | Equity | ₹0.54 Cr | 3.04% |
Fortis Healthcare Ltd | Equity | ₹0.44 Cr | 2.52% |
Alkem Laboratories Ltd | Equity | ₹0.41 Cr | 2.35% |
Torrent Pharmaceuticals Ltd | Equity | ₹0.4 Cr | 2.26% |
Mankind Pharma Ltd | Equity | ₹0.36 Cr | 2.07% |
Glenmark Pharmaceuticals Ltd | Equity | ₹0.35 Cr | 1.96% |
Zydus Lifesciences Ltd | Equity | ₹0.34 Cr | 1.95% |
Ipca Laboratories Ltd | Equity | ₹0.29 Cr | 1.65% |
Laurus Labs Ltd | Equity | ₹0.26 Cr | 1.50% |
Suven Pharmaceuticals Ltd | Equity | ₹0.23 Cr | 1.30% |
Piramal Pharma Ltd | Equity | ₹0.22 Cr | 1.27% |
Syngene International Ltd | Equity | ₹0.21 Cr | 1.21% |
Abbott India Ltd | Equity | ₹0.21 Cr | 1.18% |
Biocon Ltd | Equity | ₹0.19 Cr | 1.09% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.19 Cr | 1.08% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹0.18 Cr | 1.03% |
Gland Pharma Ltd | Equity | ₹0.18 Cr | 1.01% |
Ajanta Pharma Ltd | Equity | ₹0.18 Cr | 1.01% |
Natco Pharma Ltd | Equity | ₹0.17 Cr | 0.97% |
Neuland Laboratories Limited | Equity | ₹0.17 Cr | 0.97% |
Dr. Lal PathLabs Ltd | Equity | ₹0.16 Cr | 0.89% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.15 Cr | 0.86% |
Concord Biotech Ltd | Equity | ₹0.15 Cr | 0.83% |
Strides Pharma Science Ltd | Equity | ₹0.14 Cr | 0.82% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.14 Cr | 0.77% |
Poly Medicure Ltd | Equity | ₹0.14 Cr | 0.77% |
Global Health Ltd | Equity | ₹0.13 Cr | 0.71% |
Jubilant Pharmova Ltd | Equity | ₹0.12 Cr | 0.70% |
Wockhardt Ltd | Equity | ₹0.12 Cr | 0.69% |
Narayana Hrudayalaya Ltd | Equity | ₹0.12 Cr | 0.66% |
Granules India Ltd | Equity | ₹0.11 Cr | 0.64% |
Rainbow Childrens Medicare Ltd | Equity | ₹0.11 Cr | 0.63% |
Pfizer Ltd | Equity | ₹0.11 Cr | 0.60% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹0.09 Cr | 0.49% |
Alembic Pharmaceuticals Ltd | Equity | ₹0.08 Cr | 0.48% |
Sanofi India Ltd | Equity | ₹0.08 Cr | 0.47% |
Marksans Pharma Ltd | Equity | ₹0.08 Cr | 0.46% |
Metropolis Healthcare Ltd | Equity | ₹0.07 Cr | 0.43% |
Jupiter Life Line Hospitals Ltd | Equity | ₹0.07 Cr | 0.39% |
AstraZeneca Pharma India Ltd | Equity | ₹0.06 Cr | 0.37% |
Vijaya Diagnostic Centre Ltd | Equity | ₹0.06 Cr | 0.36% |
Ami Organics Ltd | Equity | ₹0.06 Cr | 0.36% |
Shilpa Medicare Ltd | Equity | ₹0.06 Cr | 0.35% |
Procter & Gamble Health Ltd | Equity | ₹0.06 Cr | 0.32% |
Caplin Point Laboratories Ltd | Equity | ₹0.06 Cr | 0.32% |
Glenmark Life Sciences Ltd | Equity | ₹0.04 Cr | 0.25% |
Aarti Pharmalabs Ltd | Equity | ₹0.04 Cr | 0.24% |
Net Current Assets | Cash | ₹-0.04 Cr | 0.23% |
Morepen Laboratories Ltd | Equity | ₹0.04 Cr | 0.21% |
FDC Ltd | Equity | ₹0.04 Cr | 0.21% |
Indegene Ltd | Equity | ₹0.03 Cr | 0.20% |
Kovai Medical Center & Hospital Ltd | Equity | ₹0.03 Cr | 0.20% |
Advanced Enzyme Technologies Ltd | Equity | ₹0.03 Cr | 0.18% |
Orchid Pharma Ltd | Equity | ₹0.03 Cr | 0.17% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹0.03 Cr | 0.17% |
Triparty Repo Trp_041124 | Cash - Repurchase Agreement | ₹0.03 Cr | 0.17% |
Sequent Scientific Ltd | Equity | ₹0.03 Cr | 0.17% |
Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.03 Cr | 0.16% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.03 Cr | 0.14% |
HealthCare Global Enterprises Ltd | Equity | ₹0.02 Cr | 0.14% |
Indraprastha Medical Corp Ltd | Equity | ₹0.02 Cr | 0.14% |
Krsnaa Diagnostics Ltd | Equity | ₹0.02 Cr | 0.13% |
Unichem Laboratories Ltd | Equity | ₹0.02 Cr | 0.13% |
Aarti Drugs Ltd | Equity | ₹0.02 Cr | 0.13% |
Supriya Lifescience Ltd | Equity | ₹0.02 Cr | 0.12% |
Hikal Ltd | Equity | ₹0.02 Cr | 0.11% |
Thyrocare Technologies Ltd | Equity | ₹0.02 Cr | 0.11% |
Dishman Carbogen Amics Ltd | Equity | ₹0.02 Cr | 0.10% |
Innova Captab Ltd | Equity | ₹0.02 Cr | 0.09% |
Gufic Biosciences Ltd | Equity | ₹0.02 Cr | 0.09% |
Blue Jet Healthcare Ltd | Equity | ₹0.02 Cr | 0.09% |
Indoco Remedies Ltd | Equity | ₹0.02 Cr | 0.09% |
RPG Life Sciences Ltd | Equity | ₹0.01 Cr | 0.08% |
IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.07% |
Syncom Formulation (India) Ltd | Equity | ₹0.01 Cr | 0.07% |
Hester Biosciences Ltd | Equity | ₹0.01 Cr | 0.07% |
Gujarat Themis Biosyn Ltd | Equity | ₹0.01 Cr | 0.07% |
SMS Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.07% |
Windlas Biotech Ltd | Equity | ₹0.01 Cr | 0.07% |
Bliss GVS Pharma Ltd | Equity | ₹0.01 Cr | 0.06% |
Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.01 Cr | 0.06% |
Suven Life Sciences Ltd | Equity | ₹0.01 Cr | 0.06% |
Kopran Ltd | Equity | ₹0.01 Cr | 0.06% |
Sigachi Industries Ltd | Equity | ₹0.01 Cr | 0.06% |
Themis Medicare Ltd | Equity | ₹0.01 Cr | 0.06% |
Novartis India Ltd | Equity | ₹0.01 Cr | 0.06% |
Shalby Ltd | Equity | ₹0.01 Cr | 0.05% |
Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.05% |
Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.05% |
GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.04% |
Vimta Labs Ltd | Equity | ₹0.01 Cr | 0.03% |
NGL Fine-Chem Ltd | Equity | ₹0 Cr | 0.03% |
KMC Speciality Hospitals (India) Ltd | Equity | ₹0 Cr | 0.02% |
Sastasundar Ventures Ltd | Equity | ₹0 Cr | 0.02% |
Cash Margin - Ccil | Cash - Repurchase Agreement | ₹0 Cr | 0.00% |
Large Cap Stocks
45.66%
Mid Cap Stocks
28.50%
Small Cap Stocks
24.93%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹17.36 Cr | 98.55% |
Basic Materials | ₹0.1 Cr | 0.54% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since September 2024
ISIN INF194KB1IS2 | Expense Ratio 0.22% | Exit Load No Charges | Fund Size ₹18 Cr | Age 2 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹565.80 Cr | - |
ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹565.80 Cr | - |
ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹471.41 Cr | - |
SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹670.31 Cr | - |
DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1886.93 Cr | - |
SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1190.98 Cr | - |
SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹670.31 Cr | - |
ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹471.41 Cr | - |
DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1886.93 Cr | - |
SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1190.98 Cr | - |
Your principal amount will be at Very High Risk